LRMR Larimar Therapeutics, Inc.
$3.08
Larimar Therapeutics, Inc. (LRMR) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.39 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.7% since its last earnings release on August 4, 2026.
Larimar Therapeutics Beat Consensus Estimates
Tuesday, August 4, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 7:00 AM ET
Earnings Whisper
-
vs ($0.39)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$4.03
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.